Cydan, founded with the mission to accelerate the development of treatments for rare diseases, operates as an orphan drug accelerator. The company identifies and de-risks promising biological research programs that show therapeutic and commercial potential. Cydan focuses on assets with well-understood biology and proof-of-concept data from various sources, including academia and industry. Their goal is to advance these programs to a stage where they can be further developed by pharmaceutical companies.
Notable affiliated people include experienced professionals in biotechnology and pharmaceuticals who guide the company's strategic direction. Cydan has garnered support from reputable investors, contributing to its ability to achieve significant milestones in drug development. The company has successfully advanced several programs, positively impacting the rare disease community by bringing potential treatments closer to market.
